- Home
- CLSK vs ARQT Comparison
CLSK vs ARQT Comparison
Compare CLSK & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- ARQT
- Stock Information
- Founded
- CLSK 1987
- ARQT 2016
- Country
- CLSK United States
- ARQT United States
- Employees
- CLSK N/A
- ARQT N/A
- Industry
- CLSK Finance: Consumer Services
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- CLSK Finance
- ARQT Health Care
- Exchange
- CLSK Nasdaq
- ARQT Nasdaq
- Market Cap
- CLSK 1.9B
- ARQT 2.0B
- IPO Year
- CLSK N/A
- ARQT 2020
- Fundamental
- Price
- CLSK $7.51
- ARQT $13.01
- Analyst Decision
- CLSK Strong Buy
- ARQT Strong Buy
- Analyst Count
- CLSK 7
- ARQT 6
- Target Price
- CLSK $22.00
- ARQT $18.80
- AVG Volume (30 Days)
- CLSK 27.2M
- ARQT 2.6M
- Earning Date
- CLSK 05-08-2025
- ARQT 05-06-2025
- Dividend Yield
- CLSK N/A
- ARQT N/A
- EPS Growth
- CLSK N/A
- ARQT N/A
- EPS
- CLSK 0.27
- ARQT N/A
- Revenue
- CLSK $467,488,000.00
- ARQT $196,542,000.00
- Revenue This Year
- CLSK $118.59
- ARQT $60.21
- Revenue Next Year
- CLSK $36.65
- ARQT $40.21
- P/E Ratio
- CLSK $27.49
- ARQT N/A
- Revenue Growth
- CLSK 118.07
- ARQT 229.74
- 52 Week Low
- CLSK $6.45
- ARQT $6.99
- 52 Week High
- CLSK $21.39
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- CLSK 47.80
- ARQT 41.36
- Support Level
- CLSK $6.45
- ARQT $12.51
- Resistance Level
- CLSK $8.15
- ARQT $13.67
- Average True Range (ATR)
- CLSK 0.78
- ARQT 1.45
- MACD
- CLSK 0.06
- ARQT -0.32
- Stochastic Oscillator
- CLSK 62.49
- ARQT 20.65
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.